The New England Journal of Medicine Questions Distributing HPV Vaccines
This article states that the New England Journal of Medicine has posted articles questioning the distribution of GARDASIL, manufactured by Merck & Co. Inc and Cervarix, manufactured by GlaxoSmithKline, the two leading human papilloma virus vaccines being dispensed to girls and women worldwide.
From the article:
The New England Journal of Medicine posted two articles this week that asked why two human papillomavirus vaccines have been so widely distributed given their unproven effectiveness and high costs.
Studies have been underway for the distribution of HPV vaccines in the male population worldwide.
From my article, What's the Latest News on GARDASIL? :
Human papilloma viruses, more commonly called HPVs, are numerous genotypes causing various human warts, like the common warts found on hands and feet, plantar warts, and genital warts, including some 15 known strains associated with the production of cervical cancer.
Makers of the drug and its proponents have been claiming GARDASIL prevents cervical cancer, an unsubstantiated claim as girls and women involved in initial drug trials, who numbered less than 30,000, were not tracked until the usual age of the onset of cervical cancer, which occurs between the ages of 35 to 45. The average length of follow up study was less than five years.
A link to the article entitled, Human Papilloma Vaccination - Reasons for Caution, appearing in the New England Journal of Medicine.
An extract from an article, Human Papillomavirus Vaccine in Males, can be found here.
Both articles appear in the August 21, 2008 edition of the New England Journal of Medicine.
Please view the videos posted with this article.